CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis

Related Experiment Video

Updated: Aug 17, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

A P M P Marino1, A A Silva, P V A Santos

  • 1Laboratório de Autoimunidade e Imuno-regulação, Departamento de Imunologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, 21040-900, Brasil.

Memorias Do Instituto Oswaldo Cruz
|June 18, 2005
PubMed

Insights

Understanding Trypanosoma cruzi myocarditis requires exploring CC-chemokines. Targeting CC-chemokine receptors with Met-RANTES offers a promising therapeutic strategy for Chagas disease, aiding parasite control while reducing inflammation.

Area of Science:

  • Immunology
  • Parasitology
  • Cardiovascular Research

Background:

  • Trypanosoma cruzi infection causes myocarditis, leading to heart dysfunction.
  • Inflammation is a key factor in Chagas disease pathogenesis.
  • CC-chemokines and their receptors are implicated in inflammatory responses.

Purpose of the Study:

  • To investigate the role of CC-chemokines and their receptors in Trypanosoma cruzi-elicited myocarditis.
  • To evaluate the therapeutic potential of CC-chemokine receptor inhibition in T. cruzi infection.

Main Methods:

  • Analysis of augmented expression of CCL5/RANTES and CCL3/MIP-1alpha, and their receptor CCR5 in infected mouse hearts.
  • Utilizing a CC-chemokine receptor inhibitor, Met-RANTES, in experimental models.

Main Results:

  • Elevated levels of CCL5/RANTES, CCL3/MIP-1alpha, and CCR5 were observed in the hearts of T. cruzi-infected mice.
  • Met-RANTES demonstrated the involvement of CC-chemokines in T. cruzi infection.

Conclusions:

  • CC-chemokines play a significant role in the pathogenesis of Trypanosoma cruzi-induced myocarditis.
  • CC-chemokine receptors represent a potential therapeutic target for Chagas disease management.
  • Inhibiting CC-chemokine receptors may offer a strategy to ameliorate inflammation without compromising parasite control.

More Related Videos

Chemical Cartography Approaches to Study Trypanosomatid Infection08:21

Chemical Cartography Approaches to Study Trypanosomatid Infection

Published on: January 21, 2022

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

Related Concept Videos

American Trypanosomiasis01:22

American Trypanosomiasis

Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: